Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.](https://figures.cochat.ai/paper-figures/f5a1d5f19b404395b158e0a3c37f4275/fosmanogepix-a-review-of-the-first-in-class-broad-spectrum-agent-for-the-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix is a first in class Gwt1 fungal protein inhibitor, which is a class of proteins necessary for mannoprotein anchoring to the cell membrane and cell wall.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, with a wide tissue distribution, high oral bioavailability, and availability in both IV and oral formulations, FMGX provides drug characteristics that are favorable for treating invasive fungal infections, such as candidemia/invasive candidiasis caused by C. auris (24, 25).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“This novel mechanism provides a broad range of activity against Candida spp. including drug-resistant Candida.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Peter, O., & Menon, A. K. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700002-jlr200 · Cited by 403
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., O’Brien, B., Chaturvedi, V., Berkow, E., Vallabhaneni, S., Forsberg, K., Chaturvedi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6901a2 · Cited by 246
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Research works printed but not linked: 4
- Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17–20). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1–1377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
- Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12–15). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1–843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA.
- Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21–24). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain.
- Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1–1378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
Cited by
Items 201–228 of 228
Malhotra, S., & Krogstad, P. A. (2025) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaf106
Antifungal drugs, resistance towards them, and their mechanisms
Sambre, S., Chavan, P., Girse, H., & Gajbhiye, K. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29273-6.00002-3
Modern trends in the development of antifungal agents
Avtonomova, A. V., Валерьевна, К. О., Zagainova, A. V., & Makarov, V. V. (2025) · Экология человека · doi:10.17816/humeco695458
Blood protein thwarts deadly fungal disease
Mar, K. B., & Hohl, T. M. (2026) · Nature · doi:10.1038/d41586-025-03985-7
Avtonomova, A. V., Валерьевна, К. О., Lysenkova, L. N., & Krasnopolskaya, T. S. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-9-10-62-76
Al‐Obaidi, M. M., Nematollahi, S., Hayes, J. F., & Nix, D. E. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2651278
Etude structurale du remodeleur de la chromatine RSC chez Candida albicans
Dupeyron, R. (2023) · theses.fr (ABES) · doi:10.70675/5f7d1879zcfb3z42d7z91e1z9a2a37a29c1f
Surgical Management of Pulmonary Mucormycosis
Jindal, P., & Kalra, S. (2026) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2026.02.010
Purssell, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-03964-4_6
Candida (Candidozyma) auris strains exposed to azole fungicides become less susceptible to manogepix
Boutillier, A., Baillod, A., Moreau, J., Labanowski, J., Marchand, S., Clarhaut, J. A., & Brunet, K. (2026) · Medical Mycology · doi:10.1093/mmy/myag041
Invasive mold infections in the pediatric setting: current status and new developments
Warris, A., Rojo, P., Groll, A. H., & Arrieta, A. C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2672541
Fungal Infections and Climate Change: Emerging Threats, Future Directions, and Clinical Implications
Chastain, D. B., George, M. E., Cluck, D. B., & Henao‐Martínez, A. F. (2026) · Springer eBooks · doi:10.1007/978-3-032-21237-5_15
Antifungal peptides for biofilm disruption: Mechanisms, design strategies, and translational outlook
Saini, Y., Wani, M. Y., & Hameed, S. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108601 · Cited by 1
Hameed, T., John, L. L. H., Bignell, E., & Tanaka, R. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733372
Vardanyan, R., & Vardanyan, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-51186-8.00012-9
Ozanique, P. R., Avesani, J. G. G., & Regasini, L. O. (2026) · Springer eBooks · doi:10.1007/978-3-642-36202-6_246-1
Clinical implications in patients with isolation of Candidozyma auris in a single tertiary hospital
Kim, T., Kim, Y. J., & Lee, Y. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13963-7
Management of invasive fungal infections in the intensive care unit
Chean, D., Friol, A., Azoulay, É., & Maillard, A. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2710718
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Bratosin, F., Bogdan, I. G., & Pescariu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12100733
Molecular mechanisms, pathogenesis and therapeutic advances of Candida albicans in oral candidiasis
Sahu, B. K., Debta, P., Patra, S. K., Sahu, M. C., Mohanta, T. K., & Panda, S. K. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1918424 · Cited by 1
Disseminated Fusarium infection following cladribine chemotherapy for hairy-cell leukaemia
Dandan, M., Anwer, S., Kidwell, A., & Aldrete, S. D. M. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-271236
Taman, M., Teshome, A., Porto, C. M., Dailey, J. M., Tung, G., Burns, R. H., Punsoni, M., Farmakiotis, D., & Malik, A. N. (2026) · World Neurosurgery · doi:10.1016/j.wneu.2026.125354
Dharmapalan, D., Singh, M., El-Shabrawi, M. H. F., Murray, T. S., Sadoh, A. E., Simental, L. P. S., Ibanes-Gutiérrez, C., Efstathiou, E., Fathy, H. M., Rath, B. A., et al. (2026) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2026.1970689
The Antifungal Pipeline: New and Future Antifungals
Hendrix, C., Blum, S., Zuniga-Moya, J. C., Spec, A., & Rauseo, A. M. (2026) · Current Clinical Microbiology Reports · doi:10.1007/s40588-026-00280-5
Hua, T., Bott, N., & Phan, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-2300-9_10-1
Metadata
- Authors
- Shaw, K. J., & Ibrahim, A. S.
- Affiliations
- Hearts Consulting Group, LLC, Poway, CA 92064, USA
- University of California, Los Angeles (US)
- Corresponding author
- Shaw, Karen Joy
- Ibrahim, Ashraf S.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-10-22
- Volume
- 6
- Issue
- 4
- Pages
- 239
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7711534
- OpenAlex
- W3093555016
- Cited by
- 229
- References
- 64
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 36 · 2023: 47 · 2022: 30 · 2021: 25
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, manogepix, invasive fungal infections, antifungal drug development, Candida, Aspergillus, echinocandin resistance, azole resistance, Scedosporium, Lomentospora prolificans, Fusarium, Mucorales, oral bioavailability, drug-drug interactions, drug tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.